Pluristem's PLX Cells Reduce Fibrotic Processes

Pluristem's PLX Cells Reduce Fibrotic Processes

  Potential to Address Multi-Billion Markets Where Fibrosis is End Stage of
                             Inflammatory Process

 Data to be Presented at the Israel Society for Placenta Research Conference

HAIFA, Israel, Oct. 17, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc.
(Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell
therapies, today announced that a reduction of fibrotic processes has been
demonstrated in preclinical and in in-vitro studies using Pluristem's
Placental eXpanded (PLX) cells. Lena Pinzur MSc, Pluristem's Basic and
Preclinical Research Manager will present data at the 3rd Annual Meeting of
the Israel Society for Placenta Research on October 18, 2012.

"Demonstrating that our PLX cells can potentially act as potent anti-fibrotic
agents positions us to penetrate several multi-billion dollar markets where
fibrosis is the end stage of an inflammatory process," said Zami Aberman,
Chairman and CEO of Pluristem. "We will continue our research into this
important characteristic of our cells that will enable us to add the
prevention of fibrosis to our growing list of indications for our PLX cells."

Fibrosis, defined as the overgrowth, hardening, and/or scarring of various
tissues as the end result of chronic inflammation, can result from a variety
of stimuli that includes chronic infections, autoimmune reactions, allergic
responses, chemical and radiation insults, radiation, and other causes of
tissue injury. Fibrosis can occur in virtually any organ, including the heart,
liver, kidney and lung. The fibrotic reaction is attributed to an excessive
deposition of extracellular matrix components including collagen and
fibronectin.

The basis for Pluristem's hypothesis that PLX cells act as anti-fibrotic
agents comes from animal models given Bleomycin, an anti-cancer agent, known
to induce pulmonary fibrosis and widely used to study the mechanisms involved
in fibrogenesis. Bleomycin induces chromosomal DNA strands to break, which
results in pulmonary inflammation and subsequent fibrosis.

In the experiments, 8-10 week old male mice were randomized to receive
Bleomycin alone or Bleomycin plus PLX cells administered into the trachea.
Mice that received only Bleomycin served as controls. Pertinent results at 21
days include a statistically significant improvement in oxygen saturation
(p<0.05), monitored on a weekly basis during the study and a significant
reduction in the collagen (p <0.001) deposition in the lungs when examined
histologically. This information may suggest that the PLX cells are reactive
to the fibrotic environment.

About Pluristem Therapeutics

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR) is a leading developer
of placenta-based cell therapies. The Company's patented PLX (PLacental
eXpanded) cells are a drug delivery platform that releases a cocktail of
therapeutic proteins in response to a host of local and systemic inflammatory
and ischemic diseases. PLX cells are grown using the company's proprietary 3D
micro-environmental technology and are an "off-the-shelf" product that
requires no tissue matching prior to administration. Pluristem is focusing on
the development of PLX cells administered locally to potentially treat
systemic diseases and potentially obviating the need to use the intravenous
route.

Data from two phase I studies indicate that Pluristem's first PLX product
candidate, PLX-PAD, is safe and potentially effective for the treatment of end
stage peripheral artery disease when given locally. Additionally, Pluristem is
developing PLX-PAD for cardiac ischemia; PLX-BMP for Acute Radiation Exposure,
Bone Marrow Transplant Failure and Chemotherapy induced Bone Marrow Aplasia,
PLX-ORTHO for orthopedic indications and PLX-PAH for Pulmonary Hypertension in
collaboration with United Therapeutics. Pluristem's pre-clinical animal models
have demonstrated PLX cells are also potentially effective in other
inflammatory/ischemic indications, including diastolic heart failure,
inflammatory bowel disease, neuropathic pain and pulmonary fibrosis.

Pluristem has a strong patent and patent applications portfolio, company-owned
GMP certified manufacturing and research facilities, strategic relationships
with major research institutions and a seasoned management team. For more
information visit www.pluristem.com, follow Pluristem on Twitter@Pluristem,
the content of which is not part of this press release.

The Pluristem Therapeutics Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=6882

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995 and federal securities laws. For example, when we discuss that PLX
cells can potentially act as anti-fibrotic agents to reduce fibrotic
processes, that PLX cells can potentially address multi Billion markets where
Fibrosis in the end stage of inflammatory process, that our products can
potentially treat systemic diseases and potentially obviate the need to use
the intravenous route, that data from two phase I indicates that PLX-PAD is
safe and potentially effective for the treatment of end stage peripheral
artery disease, when we discuss other product candidates that we develop and
their intended use, or when we discuss how pre-clinical animal models have
demonstrated PLX cells are also potentially effective in other
inflammatory/ischemic indications, we are using forward-looking statements.
These forward-looking statements are based on the current expectations of the
management of Pluristem only, and are subject to a number of factors and
uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements. The following factors, among
others, could cause actual results to differ materially from those described
in the forward-looking statements: changes in technology and market
requirements; we may encounter delays or obstacles in launching and/or
successfully completing our clinical trials; our products may not be approved
by regulatory agencies, our technology may not be validated as we progress
further and our methods may not be accepted by the scientific community; we
may be unable to retain or attract key employees whose knowledge is essential
to the development of our products; unforeseen scientific difficulties may
develop with our process; our products may wind up being more expensive than
we anticipate; results in the laboratory may not translate to equally good
results in real surgical settings; results of preclinical studies may not
correlate with the results of human clinical trials; our patents may not be
sufficient; our products may harm recipients; changes in legislation;
inability to timely develop and introduce new technologies, products and
applications; loss of market share and pressure on pricing resulting from
competition, which could cause the actual results or performance of Pluristem
to differ materially from those contemplated in such forward-looking
statements. Except as otherwise required by law, Pluristem undertakes no
obligation to publicly release any revisions to these forward-looking
statements to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events. For a more detailed
description of the risks and uncertainties affecting Pluristem, reference is
made to Pluristem's reports filed from time to time with the Securities and
Exchange Commission.

CONTACT: Pluristem Therapeutics Inc.:
        
         William Prather R.Ph., M.D. Sr. VP Corporate Development
         1-303-883-4954
         William.PratherMD@pluristem.com
        
         Daya Lettvin
         Investor & Media Relations Director
         +972-54-674-5580
         daya@pluristem.com

Pluristem Therapeutics Inc. Logo
 
Press spacebar to pause and continue. Press esc to stop.